Did you know?

Chartbook #214: Why the 2023 banking crisis does not look like 2008, or why one run is not like another.WebSome thoughts on AUPH: 1. As cited, AUPH reported Lupkynis sales +46% YOY, +20% over Q1, and raised full year guidance to $150 million - $160 million, but admittedly is only scratching the surface ...2021-12-28 Short sale volume (not short interest) for $FSR is 66%. http://shortvolumes.com/?t=FSR $KDP 44% $TNA 40% $SPDW 77% $AUPH 41%. 29 Dec 2021WebM&A season started some weeks ago with Trilium / Pfizer, Sanofi bought Kadmon, etc... AUPH is one of the best candidate for the big pharmas. A weird Press Release appeared a couple of weeks ago on different websites, about a 35+ acquisition by a big pharma, it was later asked to be removed by the company from Benzinga. The short interest Nov 24, 2023 · View real-time AUPH stock price and news, along with industry-best analysis. Explore Our Brands. WSJ; ... Short Interest Change-0.88%: Percent of Float: 13.23%: Advanced $ 1D. Compare. Peers. Name ... Nov 21, 2023 · Aurinia Pharmaceuticals ( NASDAQ: AUPH) soared 6.7% amid takeover speculation. The Aurinia ( AUPH) stock surge comes amid a report that a Gilead Sciences ( GILD) corporate jet made a trip to ... In the most recent earnings period of Q1 of 2023, Aurinia Pharmaceuticals Inc. reported 59% year-over-year growth in revenue of LUPKYNIS™ to $34.4 million. Full-year 2023 revenue guidance range ...Aurinia Pharmaceuticals ( NASDAQ: AUPH) rose 6.5% amid renewed takeover speculation. There's speculation than unnamed suitor may be eyeing a takeover of Aurinia ( AUPH ), according to a Betaville ...Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Free Report) (TSE:AUP) was the target of a large increase in short interest in September. As of September 15th, there was short interest totalling ...Aurinia Pharmaceuticals (AUPH) Short Interest Ratio & Short Volume $8.85 -0.39 (-4.22%) (As of 03:22 PM ET) Compare Today's Range $8.77 $10.05 50-Day Range $7.13 $9.24 52-Week Range $4.07 $12.43 Volume 6.25 million shs Average Volume 2.60 million shs Market Capitalization $1.27 billion P/E Ratio N/A Dividend Yield N/A Price Target $14.00The u/AnalystRipper community on Reddit. Reddit gives you the best of the internet in one place.Get the latest CymaBay Therapeutics Inc (CBAY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.The mean of analysts' price targets for Aurinia (AUPH) points to a 59.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ...WebAs of November 15th, there was short interest totaling 30,500 shares, a decrease of 27.2% from the October 31st total of 41,900 shares. Based on an average daily volume of 37,400 shares, the short-interest ratio is presently 0.8 days. Currently, 1.0% of the company's shares are sold short. ... (AUPH), Arch Therapeutics ...WebMar 23, 2023 · For fiscal 2023, the company expects LUPKYNIS revenue to be between $120 million and $140 million, representing annual growth of 15.4% to 34.6% in terms of net product sales. While analysts expect ... Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Free Report) (TSE:AUP) was the target of a large increase in short interest in September. As of September 15th, there was short interest totalling ...Short Interest Change. -0.88%. Percent of Float. 13.2For 2022, Aurinia ( AUPH) projects net re Oct 29, 2021 · Zhanna Hapanovich/iStock via Getty Images. Aurinia Pharmaceuticals (NASDAQ: AUPH) may be worth $45-$53/share in a possible sale and may see interest from other pharma cos. besides Bristol Myers ... Short interest is the volume of POINT Biopharma Global shares that have been sold short but have not yet been covered or closed out. As of October 31st, traders have sold 4,390,000 shares of PNT short. 5.09% of POINT Biopharma Global's shares are currently sold short. Learn More on POINT Biopharma Global's current short interest. According to Business Dictionary, a loan d Jul 7, 2023 · NP. VQNPX - Vanguard Growth and Income Fund Investor Shares This fund is a listed as child fund of Vanguard Group Inc and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value. 28,200. -40.63. Dec 1, 2023 · The company has $337.90 million in cash and $93.21 million in debt, giving a net cash position of $244.69 million or $1.70 per share. Cash & Cash Equivalents. 3 Agu 2023 ... The increase in other income is

May 22, 2023 · @PITX3 not really great short squeeze potential, more like short caress. 11% of float takes 5 - 6 days to cover. From mid-April to mid-May the short position decreased by 2M down to 15.5M, 11% of ... Jul 18, 2023 · Learn more about AUPH stock here. Skip to content. Explore Alpha Picks; ... Interest income rose to $3.8 million due to higher yields from increased interest rates. ... cash equivalents, and short ... Nov 21, 2023 · Aurinia Pharmaceuticals ( NASDAQ: AUPH) soared 6.7% amid takeover speculation. The Aurinia ( AUPH) stock surge comes amid a report that a Gilead Sciences ( GILD) corporate jet made a trip to ... Short Interest. Most Shorted. Largest Increase. Largest Decrease. ... The analyst firm set a price target for $15.00 expecting AUPH to rise to within 12 months (a possible 67.41% upside).This short interest tracker provides a variety of short interest related data, sourced from a variety of partners. The data is organized by …

A short bio should include an introduction, information about education, relevant information regarding awards and achievements, and a conclusion. Depending on the purpose of the bio, it may also include relevant work experience and qualifi...Based on recent acquisitions, Aurinia ( AUPH) would be more likely to see $18–$20 per share in a takeover, RBC analyst Douglas Miehm, who has an outperform rating with a $13 price target on AUPH ...Aurinia Pharma ( NASDAQ: AUPH) is scheduled to announce Q3 earnings results on Thursday, November 2nd, before market open. The consensus EPS Estimate is -$0.17 vs -$0.06 in 3Q22 and the consensus ...…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Short Float / Ratio: 13.17% / 8.88: Perf Quarter-4.23%: Sales: 15. Possible cause: Arrow Financial Co. (NASDAQ:AROW – Get Rating) was the recipient of a significant increas.